Sprays are often recommended for better absorption rates
Gastrointestinal symptoms: Some peptides, especially GLP-1 receptor agonists such as semaglutide or tirzepatide, can slow digestion, which may lead to nausea, vomiting, diarrhea, or constipation
It produced roughly 24% body weight loss in trials, more than semaglutide or tirzepatide
Food and Drug Administration (FDA), the approved dosages for some of the commonly prescribed GLP-1 agonists are as follows: Semaglutide (Ozempic): 0.5 mg, 1 mg, or 2 mg once weekly for type 2 diabetes, and up to 2.4 mg once weekly for chronic weight management (marketed as Wegovy)
There may be instances where certain conditions, such as poor nutrition, intestinal issues, infections, and cancer, may lead to B12 deficiency